
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
New York-The incidence of skin disease is not significantly different among Latinos than with other patient groups, but physicians who treat Latino patients need to be aware of some differences in the frequency of diagnosis as well as the cultural aspects of treatment, Miguel R. Sanchez, M.D., said.






